Ibrutinib (Ibr) dose modification for management of early cardiac adverse events in patients with chronic lymphocytic leukemia: Pooled analysis of 7 clinical trials.

Autor: Tedeschi, A., Ahn, I. E., Fraser, G. A. M., Greil, R., Munir, T., Kay, N. E., Flinn, I. W., Lee, S., Saifan, C., Kearbey, J., Patel, S., Barrientos, J. C.

Publikováno v: Hematological Oncology; Jun2023 Supplement S2, Vol. 41, p461-463, 3p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Zilovertamab vedotin (MK‐2140) in relapsed or refractory (R/R) non‐Hodgkin lymphoma (NHL): 14‐month follow‐up of the phase 1 waveLINE‐001 study.

Autor: Wang, M. L., Mei, M., Barr, P. M., Barrientos, J. C., de Vos, S., Furman, R. R., Patel, K., Wierda, W. G., Choi, M. Y., Kallam, A., Wang, S., Ogbu, U. C., Marinello, P., Spurgeon, S. E.

Publikováno v: Hematological Oncology; Jun2023 Supplement S2, Vol. 41, p571-572, 2p

Phase 2 study of ibrutinib in relapsed or refractory mantle cell lymphoma:updated safety analysis on prevalence of infection, diarrhea, and bleeding over time

Autor: Rule, S., Wang, M. L., Martin, P., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J., Williams, M., Barrientos, J. C., Chmielowska, E., Radford, J. A., Stilgenbauer, S., Truong, V., Chang, M., Beaupre, D. M., Goy, A., Blum, K. A.

Publikováno v: Rule, S, Wang, M L, Martin, P, Auer, R, Kahl, B S, Jurczak, W, Advani, R H, Romaguera, J, Williams, M, Barrientos, J C, Chmielowska, E, Radford, J A, Stilgenbauer, S, Truong, V, Chang, M, Beaupre, D M, Goy, A & Blum, K A 2014, ' Phase 2 study of ibrutinib in relapsed or refractory mantle cell lymphoma : updated safety analysis on prevalence of infection, diarrhea, and bleeding over time ', Haematologica, vol. 99, no. Supplement 1, P461, pp. 150-150 . < https://haematologica.org/article/view/7071 >

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3818::af501d68e07e25c12ae51e87912846a1
https://www.research.manchester.ac.uk/portal/en/publications/phase-2-study-of-ibrutinib-in-relapsed-or-refractory-mantle-cell-lymphoma(8fb572b1-7906-46f9-8d38-1640ff64d984).html

PB1878: CROSS‐TRIAL ANALYSIS OF FIXED‐DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST‐LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Autor: Barrientos, J. C., Barr, P. M., Mato, A. R., Tam, C. S., Ghia, P., Moreno, C., Kay, N. E., Siddiqi, T., Szafer‐Glusman, E., Zhou, C., Neumayr, L., Krigsfeld, G., Wierda, W. G., Shanafelt, T.

Publikováno v: HemaSphere; 2022 Supplement 3, Vol. 6, p1758-1759, 2p